Abstract
It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cell-mediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abrams SI . (2004). Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opin Mol Ther 6: 71–77.
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678–689.
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P et al. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303–1316.
Blank C, Mackensen A . (2007). Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739–745.
Bosque A, Pardo J, Martinez-Lorenzo MJ, Lasierra P, Larrad L, Marzo I et al. (2005). Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur J Immunol 35: 1812–1821.
Bron LP, Scolyer RA, Thompson JF, Hersey P . (2004). Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 36: 561–565.
Bronte V, Zanovello P . (2005). Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641–654.
Bui JD, Schreiber RD . (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19: 203–208.
Chang CC, Ferrone S . (2007). Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56: 227–236.
Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L et al. (2003). Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63: 9007–9015.
Curiel TJ . (2007). Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167–1174.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.
Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP et al. (2005). Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11: 728–734.
Dudley ME, Rosenberg SA . (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666–675.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850–854.
Dunn GP, Koebel CM, Schreiber RD . (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836–848.
Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al. (2005). Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591–1602.
Espana L, Fernandez Y, Rubio N, Torregrosa A, Blanco J, Sierra A . (2004). Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat 87: 33–44.
Ferris RL, Whiteside TL, Ferrone S . (2006). Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12: 3890–3895.
Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546–2553.
Flies DB, Chen L . (2007). The new B7s: playing a pivotal role in tumor immunity. J Immunother (1997) 30: 251–260.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027–1034.
Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH et al. (2007). Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 13: 4840–4848.
Gallimore A, Sakaguchi S . (2002). Regulation of tumour immunity by CD25+ T cells. Immunology 107: 5–9.
Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y et al. (1999). A ‘stealth effect’: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 163: 4886–4893.
Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF et al. (2005). Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27: 611–615.
Greeneltch K, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K et al. (2007). Host immunosurveillance controls tumor growth via IRF-8-dependent mechanisms. Cancer Res 67: 10406–10416.
Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.
Harizi H, Juzan M, Grosset C, Rashedi M, Gualde N . (2001). Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol 209: 19–28.
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089–1096.
Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT et al. (2002). Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553–2562.
Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F et al. (1996). Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307–317.
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H . (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404–4408.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293–12297.
Jung YJ, Kim JY, Park JH . (2004). TGF-beta1 inhibits Fas-mediated apoptosis by regulating surface Fas and cFLIPL expression in human leukaemia/lymphoma cells. Int J Mol Med 13: 99–104.
Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S . (1996). Fas expression and function in normal and malignant breast cell lines. Cancer Res 56: 4791–4798.
Kim R, Emi M, Tanabe K, Uchida Y, Toge T . (2004). The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100: 2281–2291.
Koneru M, Schaer D, Monu N, Ayala A, Frey AB . (2005). Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 174: 1830–1840.
Korman AJ, Peggs KS, Allison JP . (2006). Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297–339.
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314–1321.
Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM et al. (2006). B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391–10396.
Krammer PH, Galle PR, Moller P, Debatin KM . (1998). CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res 75: 251–273.
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. (2006). B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: 871–881.
Kusmartsev S, Gabrilovich DI . (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237–245.
Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL . (2004). Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755–3762.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261–268.
Leach DR, Krummel MF, Allison JP . (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736.
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al. (1999). Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5: 677–685.
Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA . (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99–146.
Lin EY, Pollard JW . (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064–5066.
Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C . (2007). The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192–3201.
Liu K, Abrams SI . (2003a). Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 170: 5973–5980.
Liu K, Abrams SI . (2003b). Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. J Immunol 170: 6329–6337.
Liu K, Caldwell SA, Abrams SI . (2005a). Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. Cancer Res 65: 1045–1054.
Liu K, Caldwell SA, Abrams SI . (2005b). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 65: 4376–4388.
Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI . (2006). CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 176: 3374–3382.
Liu K, McDuffie E, Abrams SI . (2003). Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol 171: 4164–4174.
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756–2761.
Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB et al. (2006). Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402–3409.
Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66: 9299–9307.
Nagaraj S, Gabrilovich DI . (2007). Myeloid-derived suppressor cells. Adv Exp Med Biol 601: 213–223.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319–322.
Ochoa AC, Zea AH, Hernandez C, Rodriguez PC . (2007). Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: 721s–726s.
Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H et al. (1999). Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96: 2233–2238.
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N et al. (2005). Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947–2953.
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F . (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457–2464.
Otten GR, Germain RN . (1991). Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251: 1228–1231.
Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569–580.
Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL . (2000). Fas and Fas ligand interactions in malignant disease. Int J Oncol 17: 5–12.
Pardoll D . (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807–839.
Pawelec G, Ouyang Q, Colonna-Romano G, Candore G, Lio D, Caruso C . (2002). Is human immunosenescence clinically relevant? Looking for ‘immunological risk phenotypes’. Trends Immunol 23: 330–332.
Penn I . (1999). Posttransplant malignancies. Transplant Proc 31: 1260–1262.
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–8377.
Pollard JW . (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.
Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C et al. (2006). A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12: 3381–3388.
Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB et al. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931–939.
Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P et al. (2007). Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 13: 4016–4025.
Sakaguchi S . (2004). Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–562.
Schmielau J, Finn OJ . (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61: 4756–4760.
Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I . (2004). High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64: 6337–6343.
Shevach EM . (2000). Regulatory T cells in autoimmmunity*. Annu Rev Immunol 18: 423–449.
Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H et al. (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849–861.
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S . (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507–4513.
Smyth MJ, Dunn GP, Schreiber RD . (2006). Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1–50.
Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA . (2000). Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192: 755–760.
Steinman RM, Hawiger D, Nussenzweig MC . (2003). Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711.
Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI . (2007). Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Exp Rev Mol Med 9: 1–20.
Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P et al. (2007). Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 67: 5454–5460.
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM . (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713–6721.
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S et al. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94–100.
Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD et al. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1: 515–520.
Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. (2003). Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741–1752.
Thomas DA, Massague J . (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369–380.
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al. (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381–3385.
Vakkila J, Lotze MT . (2004). Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641–648.
van Elsas A, Hurwitz AA, Allison JP . (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355–366.
Vogelstein B, Kinzler KW . (2004). Cancer genes and the pathways they control. Nat Med 10: 789–799.
von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P . (1998). Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526–534.
Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48–54.
Whiteside TL . (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3–15.
Willimsky G, Blankenstein T . (2005). Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141–146.
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766–4772.
Worth LL, Lafleur EA, Jia SF, Kleinerman ES . (2002). Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9: 823–827.
Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T et al. (2007). Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 67: 3301–3309.
Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409–421.
Yu H, Kortylewski M, Pardoll D . (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41–51.
Zamanakou M, Germenis AE, Karanikas V . (2007). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111: 69–75.
Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044–3048.
Zhou G, Drake CG, Levitsky HI . (2006). Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628–636.
Acknowledgements
This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stewart, T., Abrams, S. How tumours escape mass destruction. Oncogene 27, 5894–5903 (2008). https://doi.org/10.1038/onc.2008.268
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.268
Keywords
This article is cited by
-
A promising target for breast cancer: B7-H3
BMC Cancer (2024)
-
Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression
Cell Communication and Signaling (2021)
-
Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation
Scientific Reports (2021)
-
Identification of primordial germ cell-like cells as liver metastasis initiating cells in mouse tumour models
Cell Discovery (2020)
-
Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
British Journal of Cancer (2019)